
Please try another search
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Name | Age | Since | Title |
---|---|---|---|
David S. Perlin | - | 2015 | Member of Scientific Advisory Board |
Oliver Cornely | - | 2018 | Member of Scientific Advisory Board |
Dimitrios P. Kontoyiannis | - | 2018 | Member of Scientific Advisory Board |
Evelyn D’An | 62 | 2025 | Independent Director |
Keith E. Murphy | 53 | 2025 | Independent Director |
Edward Alan Neugeboren | 56 | 2025 | Independent Director |
Robin L. Smith | 64 | 2025 | Independent Director |
Jerome D. Jabbour | 51 | 2013 | Co-Founder, Chairman, CEO and President |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review